CAS 1197-17-7
:acido cis-4-aminometilcicloesano-1-carbossilico
- Tranexamic acid cis-form
- cis-AMCHA
- cis-4-(Aminomethyl)cyclohexanecarboxylic acid
- 4-(Aminomethyl)Cyclohexane-1-Carboxylic Acid
- cis-4-Aminomethylcyclohexane-1-carboxylic acid
Cyclohexanecarboxylic acid, 4-(aminomethyl)-, cis-
CAS:Formula:C8H15NO2Purezza:96%Colore e forma:SolidPeso molecolare:157.2102cis-4-(Aminomethyl)cyclohexanecarboxylic acid
CAS:cis-4-(Aminomethyl)cyclohexanecarboxylic acidPurezza:98%Peso molecolare:157.21g/molTranexamic Acid EP Impurity B
CAS:Formula:C8H15NO2Colore e forma:White To Off-White SolidPeso molecolare:157.21cis-Tranexamic Acid
CAS:Prodotto controllatoFormula:C8H15NO2Colore e forma:White To Light BeigePeso molecolare:157.21Ref: ST-EA-CP-T10002
10mgPrezzo su richiesta25mgPrezzo su richiesta50mgPrezzo su richiesta100mgPrezzo su richiestatrans-4-(Aminomethyl)cyclohexanecarboxylic acid
CAS:Trans-4-(aminomethyl)cyclohexanecarboxylic acid (AMCA) is a histamine antagonist that is used to treat bowel disease. It may also be useful for the treatment of other inflammatory diseases and as an anticoagulant. AMCA has been shown to be safe and effective for the prevention of postoperative bleeding in patients who are undergoing major surgery. This drug is a potent inhibitor of platelet aggregation, but does not affect the function of erythrocytes or leukocytes. AMCA inhibits platelet aggregation by blocking the binding of adenosine diphosphate (ADP) to its receptor on platelets, thus inhibiting ADP-mediated activation of phospholipase A2 and arachidonic acid release from membranes. An increase in blood levels of AMCA may lead to cardiac toxicity and bleeding events.
Formula:C8H15NO2Purezza:Min. 95%Peso molecolare:157.21 g/molRef: 3D-IA71533
Prodotto fuori produzione








